KRAS and lung adenocarcinoma: To identify signaling pathways that may be responsible for the decreased cell viability and morphological changes induced by co-expression of mutant KRAS and EGFR, we generated gene expression profiles of the PC9 and H358 lung adenocarcinoma cells engineered to conditionally express mutant KRAS or EGFR. 24 hr after addition of Dox to PC9-TetO-KRASG12V and H358-TetO-EGFRL858R cells or to control lines with TetO-GFP we harvested RNA.